Celecoxib (Sionara (100 mg)) is a non-steroidal anti-inflammatory drug, prescribed for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, juvenile arthritis, menstrual pain, and other pain.
NEW ORLEANS, LA — A long-awaited trial suggests the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib has similar cardiovascular safety as naproxen and ibuprofen in arthritis patients at ...
Presenters noted that this was an important but unusual trial, because it examined drugs not in isolation but how they are used in combination. At the 2016 American Heart Association Scientific ...
Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — When used at moderate doses, the selective COX-2 inhibitor celecoxib was noninferior to the ...
Dec. 17, 2004 — The cyclooxygenase (COX)-2 inhibitor celecoxib (Celebrex) more than doubled the risk of cardiovascular events in subjects enrolled in the Adenoma Prevention with Celecoxib (APC) study, ...
SILVER SPRING, Md. -- An FDA advisory committee voted 15-5 Wednesday, with one abstention, that the PRECISION trial demonstrated that celecoxib (Celebrex) has comparable cardiovascular safety to ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...
Strides Pharma Global, Singapore, has received approval for celecoxib capsules, 100 mg, 200 mg and 400 mg from the Food and Drug Administration. The product is the generic of Upjohn’s Celebrex. The ...
Strides Pharma has said that its step-down wholly owned subsidiary, Strides Pharma Global Pte., Singapore, has received approval for celecoxib capsules, 100 mg, 200 mg, and 400 mg, from the United ...
The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Celecoxib (Revibra (100 mg)) is a non-steroidal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results